This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| SCB-144 | |
|---|---|
| Name | SCB-144 |
SCB-144 is a synthetic compound studied in pharmacology and toxicology contexts. It has been examined for chemical properties, biological activity, metabolic fate, legal control, and safety profiles in preclinical and forensic settings. Research on SCB-144 intersects with studies conducted by academic laboratories, regulatory agencies, and forensic laboratories.
SCB-144 is described in the literature as a synthetic small molecule with a heterocyclic core and one or more lipophilic substituents; structural analyses have compared it to analogs characterized by researchers at institutions such as Johns Hopkins University, Massachusetts Institute of Technology, Stanford University, University of Cambridge, and University of Oxford. Spectroscopic characterization has involved techniques developed at American Chemical Society-affiliated laboratories and published in journals linked to Nature Publishing Group, Wiley-VCH, and Royal Society of Chemistry. Crystallographic studies have used methods similar to those employed by teams at Max Planck Society laboratories and national facilities like Argonne National Laboratory and Diamond Light Source. Computational modeling of SCB-144's conformations has referenced force fields and protocols common to groups at European Molecular Biology Laboratory and Lawrence Berkeley National Laboratory.
Investigations into SCB-144's mechanism of action have employed paradigms established in receptor pharmacology at centers including National Institutes of Health, Scripps Research, and Karolinska Institutet. Biochemical assays have tested interactions with targets analogous to those studied for ligands evaluated at Columbia University, Yale University, and University of California, San Francisco. Studies have used radioligand binding approaches, functional assays, and signaling pathway analyses comparable to protocols from Fred Hutchinson Cancer Research Center and Dana-Farber Cancer Institute to map downstream effects. Comparative analyses have referenced mechanisms described for compounds investigated by groups at University of Melbourne, Seoul National University, and University of Toronto.
Pharmacokinetic and pharmacodynamic profiling of SCB-144 has been conducted in vitro and in vivo following methodologies common to pharmacology groups at University of Pennsylvania, Princeton University, and University of Chicago. Metabolic studies have utilized mass spectrometry platforms developed at Thermo Fisher Scientific-associated centers and analyte identification techniques used by labs at Johns Hopkins School of Medicine and Mayo Clinic. Metabolite identification has drawn on biotransformation frameworks described by researchers at University of Basel, ETH Zurich, and University of Groningen. Toxicokinetic parameters have been compared with those reported in studies from National Institute on Drug Abuse, European Monitoring Centre for Drugs and Drug Addiction, and World Health Organization technical reports.
Synthetic routes to SCB-144 have been outlined using reactions and protections standard in organic chemistry curricula at University of California, Berkeley, Imperial College London, and University of Illinois Urbana-Champaign. Published procedures invoke reagents and catalysts available from suppliers like Sigma-Aldrich and analytical methods consistent with protocols from American Society for Mass Spectrometry meetings. Scale-up considerations and purity controls mirror process chemistry practices reported by teams at Pfizer, Novartis, and Roche. Patents and filings reviewed by patent offices such as United States Patent and Trademark Office, European Patent Office, and Japan Patent Office have influenced disclosure and commercial manufacturing discussions.
Regulatory assessment of SCB-144 involves authorities including Drug Enforcement Administration, Food and Drug Administration, European Medicines Agency, Health Canada, and Australian Therapeutic Goods Administration. Scheduling and control measures have been discussed in legislative frameworks comparable to acts administered by United Kingdom Home Office and regulatory decisions referenced by Council of the European Union. Forensic guidelines for detection and reporting have been developed in conjunction with laboratories coordinated by Interpol and national forensic networks such as FBI trace programs and National Forensic Laboratory Information System initiatives.
Toxicology studies on SCB-144 have followed testing paradigms established by Organisation for Economic Co-operation and Development test guidelines and institutional animal care committees at facilities like Charles River Laboratories and Covance. Acute and chronic exposure assessments referenced methods from Centers for Disease Control and Prevention, National Toxicology Program, and European Food Safety Authority. Clinical case reports and forensic case series have been compared with reports collated by Poison Control Center networks and surveillance systems run by EMCDDA and UNODC.
The research trajectory for SCB-144 includes early synthetic reports, analytical method development, and toxicology case series produced by collaborations among universities and forensic institutes. Key milestones have been documented in conference proceedings associated with Society for Neuroscience, American Chemical Society, and Toxicology Forum. Peer-reviewed articles describing pharmacology and forensic detection have appeared in journals and proceedings similar to those published by Elsevier, Springer Nature, and specialized periodicals such as Forensic Science International and Journal of Analytical Toxicology. Ongoing studies continue in multidisciplinary networks linking academic research centers, public health agencies, and law enforcement laboratories.
Category:Synthetic compounds